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Large-scalemitochondrial DNA (mtDNA) deletions are an important cause ofmitochondrial disease, while som-
atic mtDNA deletions cause focal respiratory chain deficiency associated with ageing and neurodegenerative
disorders. As mtDNA deletions only cause cellular pathology at high levels of mtDNA heteroplasmy, an
mtDNA deletion must accumulate to levels which can result in biochemical dysfunction—a process known
as clonal expansion. A number of hypotheses have been proposed for clonal expansion of mtDNA deletions,
including a replicative advantage for deleted mitochondrial genomes inferred by their smaller size—implying
that the largest mtDNA deletions would also display a replicative advantage over smaller mtDNA deletions.
Weproposed that inmuscle fibres frompatientswithmtDNAmaintenance disorders, which lead to the accumu-
lation ofmultiplemtDNAdeletions,wewould observe the largestmtDNAdeletions spreading the furthest longi-
tudinally through individual muscle fibres by means of a greater rate of clonal expansion. We characterized
mtDNA deletions in patients with mtDNAmaintenance disorders from a range of ‘large’ and ‘small’ cytochrome
coxidase (COX)-deficient regions inskeletalmusclefibres.Wemeasured thesizeofclonallyexpandeddeletions
in 62 small and 60 large individual COX-deficient f regions. No significant difference was observed in individual
patients or in the total dataset (small fibre regionsmean 6.59 kb—large fibre regionsmean 6.51 kb). Thus no dif-
ference existed in the rate of clonal expansion throughout muscle fibres between mtDNA deletions of different
sizes; smaller mitochondrial genomes therefore do not appear to have an inherent replicative advantage in
human muscle.
INTRODUCTION
Large-scale mitochondrial DNA (mtDNA) deletions are an im-
portant cause of mitochondrial disease (1). In many patients
these are sporadic single large-scale mtDNA deletions, with
the deletion present from birth and the same in all tissues. In
other patients, there is a defect of one of the nuclear-encoded
maintenance genes and multiple mtDNA deletions develop
during life in post-mitotic tissues such as muscle, heart and
brain. In patients with mtDNA maintenance disorders the
mtDNA deletions found even in adjacent cells is different.
This is very similar to the mtDNA deletions which are implicated
in the focal cellular dysfunction observed in both ageing and
age-related neurodegenerative disease (2–5). Whatever the
origin of the large-scale single mtDNA deletion, low levels of
mtDNA deletions can be tolerated within a cell due to the multi-
copy nature of mtDNA, as a result of the compensatory effects of
wild-type mtDNA molecules. An oxidative phosphorylation
(OXPHOS) defect, often demonstrated by focal deficiency of
cytochrome c oxidase (COX) activity, will occur only when
the mtDNA deletion load accumulates to exceed a critical thresh-
old level (6). The process by which a single mtDNA species
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accumulates to predominate within a single cell is known as
clonal expansion (7,8). Understanding the mechanism by
which this occurs is therefore of paramount importance if we
are to gain insight into the progression of mitochondrial
disease and the importance of mtDNA deletions in ageing.
To date, three main hypotheses have been proposed for clonal
expansion of mtDNA mutations. Clonal expansion was initially
hypothesized to be driven by a selective advantage for deleted
mtDNA species over wild-type mtDNA molecules based upon
replicative turnover (9). This replicative advantage mechanism
suggests that the smaller deleted mtDNA molecules are repli-
cated more quickly, permitting mtDNA deletion accumulation
(10). An alternative model based on a replicative advantage
for mtDNA deletions was proposed some years later, suggesting
that the decrease in respiratory chain function associated with
mtDNA damage leads to reduced free radical production, result-
ing in slower turnover of dysfunctional mitochondria and a sub-
sequent accumulation of mtDNA deletions (11). More recently,
it has been proposed that a selective advantage is not required for
the clonal expansion of mtDNA deletions and that random
genetic drift during mtDNA replication is sufficient to allow
clonal expansion of a single mtDNA mutation within a cell
(12–14) due to relaxed mtDNA replication (15). Random
genetic drift is supported by mathematical models based on
previously demonstrated principles of mitochondrial replicative
dynamics (16). However, the observation of high levels of
mtDNA deletions in the majority of substantia nigra neurons
from aged individuals (4,5,17) makes this difficult to understand
when modelling predicts a low level of age-related COX-
deficiency (a maximum of 4% of post-mitotic cells predicted
to become COX-deficient by 80 years of age).
Until recently, the presence of a replicative advantage for
smaller mtDNA genomes had been considered unlikely based
on evidence that some pathogenic mtDNA point mutations,
which have no effect on genome size, can accumulate in post-
mitotic tissues over time (18). Furthermore, earlier studies of
replicative dynamics have shown that mtDNA molecules repli-
cate in 1–2 h (19); as this is significantly less than the half-life of
mtDNA—estimated at 1–3 weeks (20,21)—mtDNA replication
is unlikely to act as a rate-limiting step for mitochondrial turn-
over. However, a recent study utilizing a mouse model expres-
sing inducible mitochondria-targeted restriction endonuclease
Pst1 (mito-Pst1) presented evidence of a preferential accumula-
tion of genomes harbouring larger mtDNA deletions, renewing
interest in the possibility of a replicative advantage for larger
mtDNA deletions driving clonal expansion (22).
We wished to test the presence of a replicative advantage for
smaller mtDNA molecules in human tissue. The investigation of
skeletal muscle from patients with Mendelian-driven disturb-
ance of mtDNA maintenance offers an opportunity to test this
hypothesis. Muscle from these patients contains many different
deletions of different sizes, with each affected muscle fibre pos-
sessing a different, clonally expanded mtDNA deletion causing
COX-deficiency (23). The COX-deficient segment has been
shown to be of variable length, ranging from ,10 to
.1000 mm (24). These are thought to occur as a consequence
of the continuous replication of mtDNA in muscle cells, asso-
ciated with mitochondrial fission and fusion, leading to
changes in the proportion of mutant mtDNA in muscle segments.
This would eventually propagate down the length of a fibre
through the mixing of adjacent mitochondria and mitochondrial
genomes. Since each COX-deficient segment represents a differ-
ent, clonal expansion event, we hypothesized that if smaller
mitochondrial genomes replicate faster than larger genomes,
COX-deficient segments would be larger in the presence of the
smallest mtDNA molecule (Fig. 1). Thus by comparing large,
COX-deficient areas with smaller COX-deficient areas from
the same patient, we hoped to provide new insights into the
mechanism of clonal expansion in a relevant human tissue.
RESULTS
AssessingCOX-deficientmuscle fibre region length and area
Longitudinal sections of muscle biopsy underwent histochem-
ical assessment of COX activity; COX-deficient regions of
muscle fibres were targeted for investigation in this study, repre-
senting fibre areas where mitochondrial activity has been dis-
rupted to a sufficient degree by mtDNA deletion accumulation
to cause a biochemical defect. Two categories of fibre were
selected for investigation; ‘large’ (over 500 mm in length) and
‘small’ (under 200 mm in length) regions of COX-deficiency
(Fig. 2). Values were chosen based on a maximum cutting
length on the microscope/LMD system of 650 mm. The area
(mm2) of single muscle fibres isolated by laser microdissection
was determined at the time of cutting and was found to be a
more variable measurement than fibre length when extracting
fibres. However, no overlap was observed between the two
groups in terms of COX-deficient fibre area (P, 0.0001,
Mann–Whitney test); small COX-deficient fibre regions had a
mean area of 5725+3194 mm2 (range 1302–12 800 mm2) com-
pared with 32 120+10 536 mm2 (range 19 412–57 289 mm2)
for large COX-deficient regions (Fig. 3A). Although large and
small COX-deficient muscle fibre regions were selected based
upon the length of the fibre region affected by the biochemical
defect, we decided that total fibre area (mm2) isolated by laser
microdissection would be a more appropriate and reliable
measure. The area of COX-deficiency is a better measure of the
spread and accumulation of the mtDNA deletion species respon-
sible for the biochemical defect since measurements based on
length fail to take into consideration fibre-width variation.
CharacterizingmtDNAdeletion size in singleCOX-deficient
muscle fibre regions
A total of 156 COX-deficient muscle fibre regions were success-
fully amplified by long-range PCR; from this group, a single
PCR amplimer representing one individual clonally expanded
mtDNA deletion was observed in 122 muscle fibres. These cor-
responded to 62 small (under 200 mm in length) COX-deficient
fibres and 60 large (over 500 mm in length) COX-deficient fibres
which were included in the final analysis of mtDNA deletion
sizes. Amplimer sizes from these fibre groups were assessed
by gel electrophoresis, with comparison to a 1 kb DNA ladder
allowing an estimate of mtDNA deletion sizes to be obtained
(Fig. 3B). Multiple mtDNA deletions were detected in the
remaining 34 COX-deficient fibre regions which were success-
fully amplified, with an even distribution of large (15 total)
and small (19 total) COX-deficient fibre regions. These fibres
were not included in the final analysis since it was not possible
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to establish how large a region of COX-deficiency either of the
mtDNA deletion species is responsible for.
To ensure that mtDNA deletion size estimates from gel elec-
trophoresis PCR bands were a true reflection of mtDNA deletion
size, a stratified sample of 20 single fibres (10 large and 10 small
COX-deficient fibre regions) were selected for further analysis
by breakpoint sequencing. All sequenced mtDNA deletion
breakpointsareconsistentwith themtDNAdeletionsize predicted
by gel electrophoresis (mean deviation of 229+191 bp), demon-
strating that long-range PCR can be used to accurately assess
mtDNA deletion size (Table 1).
No difference in mtDNA deletion size observed in large
and small COX-deficient muscle fibre areas
Analysis of the 60 large COX-deficient fibre regions showed a
range in mtDNA deletion size from 1 to 11.5 kb, with a mean
mtDNA deletion size of 6.51+ 2.32 kb (mean+ SD). In the
62 small COX-deficient fibres, mtDNA deletion size ranged
between 0.5 and 10.5 kb, with a mean mtDNA deletion size
of 6.59+ 2.07 kb (mean+ SD) (Fig. 4A). The use of a 10 kb
long-range PCR for analysis of a significant proportion of
fibres may have caused a slight skew towards smaller deletion
sizes and decreased the average identified mtDNA deletion
size; however, the two PCR assays were used in a similar
ratio across the two data sets, and therefore should have no
impact on further data analysis. As the large and small fibre
data were not found to follow a normal distribution, a
Mann–Whitney test was used to compare the two datasets;
this identified no significant difference exists between
mtDNA deletion sizes found in large and in small COX-
deficient muscle fibre areas (P ¼ 0.5506). To ensure that no
trends linking mtDNA deletion size and affected COX-
deficient muscle fibre area in individual patients are being
masked by inclusion into the total dataset, data from individual
cases were also analyzed independently (Fig. 4B–G). No sig-
nificant difference between mtDNA deletion sizes in large and
in small COX-deficient muscle fibre areas was identified in any
of the six cases included in this study (Table 2) in keeping with
the total dataset.
Assessing the presence of a correlation between mtDNA
deletion size and COX-deficient skeletal muscle fibre area
To ensure that we were not missing a trend, correlation analysis
of mtDNA deletion size and COX-deficient fibre area in the com-
plete dataset of 122 individual fibres was undertaken. No signifi-
cant correlation was found to exist between mtDNA deletion size
and COX-deficient skeletal muscle fibre area of the 122 bio-
chemically deficient fibre regions successfully analyzed (P ¼
0.7792, Spearman correlation analysis) (Fig. 5). Separate ana-
lyses of the small and the large COX-deficient fibre region data-
sets similarly revealed no significant correlation between
mtDNA deletion size and area (mm2) of skeletal muscle fibre
COX defect (P ¼ 0.7140 and 0.7871, respectively).
As for the assessment of differences in mtDNA deletion size
between large and small COX-deficient skeletal muscle fibre
areas, data sets from each patient were individually analyzed
to preclude any trend in a single patient becoming obscured
when included within the total dataset. No significant correlation
was found to link mtDNA deletion size to the size of the area of
COX-deficiency in muscle fibres in any of the six investigated
cases (P ¼ 0.2477, 0.8572, 0.2477, 0.4438, 0.4590 and 0.8599,
respectively).
DISCUSSION
This study aimed to test the hypothesis that the clonal expansion
of large-scale mtDNA deletions, leading to focal cellular bio-
chemical defects in post-mitotic tissues in patients with mito-
chondrial disease and in ageing, is driven by a replicative
advantage for mtDNA deletions over wild-type mtDNA due to
a smaller genome size. We proposed that if mtDNA deletion
species have a replicative advantage over wild-type, based on
a smaller size and faster replication time, larger mtDNA dele-
tions would display the same replicative advantage over
smaller mtDNA deletions. In this case, we would observe the
largest mtDNA deletions accumulating at the greatest rate, and
hence spreading furthest longitudinally through skeletal
muscle fibres. However, in this study we see no significant differ-
ence in size of mtDNA deletion between laser microdissected
Figure 1. Proposed mechanism for accumulation of smaller mtDNA molecules longitudinally through muscle fibres. Illustration of increased longitudinal accumu-
lation of larger mtDNA deletions through muscle fibres, as predicted by the ‘survival of the smallest’ hypothesis (9). (A) In the presence of no mtDNA deletions,
wild-type mtDNA copy number is maintained throughout a muscle fibre over time. (B) Following mtDNA deletion formation a replicative advantage over wild-type
mtDNA, due to the smaller size of the deleted molecule, causes an increase in the mtDNA deletion level and a spread of the deleted species through the muscle fibre. (C)
The larger the size of the mtDNA deletion, the smaller the remaining genome and the greater the replicative advantage over wild-type mtDNA. A larger mtDNA
deletion size therefore leads to a faster accumulation of the deleted species over the same time span and a greater spread through a muscle fibre .
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large and small COX-deficient fibre areas from patients with
mtDNA maintenance disorders leading to COX-deficiency.
Interestingly, our study arrives at different conclusions to the
elegant studies of Moraes and colleagues who have attempted to
investigate the mechanism in different model systems. Using
transmitochondrial cybrids derived from patient fibroblasts
with high heteroplasmy levels of single, large-scale mtDNA
deletions, these authors demonstrated a replicative advantage
for mtDNA deletions over wild-type molecules in the same
cell under relaxed mtDNA copy number conditions following
ethidium bromide-driven mtDNA depletion (25). In addition,
they presented evidence to show that smaller mitochondrial
genomes accumulate more rapidly in vivo in a mitoPst1 mouse
model, developed to express a neuronal-specific inducible
mitochondrial-targeted restriction endonuclease (Pst1). The
induction of mitoPst1 causes the generation of double-strand
mtDNA breaks, with the subsequent formation of mtDNA dele-
tions closely mimicking the range of naturally occurring mtDNA
deletions found in ageing neurons. These authors reported pref-
erential accumulation of genomes harbouring larger mtDNA
deletions compared with smaller mtDNA deletions, concluding
that this was due to a replicative advantage for smaller mitochon-
drial genomes (22).
A possible explanation for the discrepancies between our
results and the findings from previous studies is that there are
times when replication rate does become rate limiting. The
data of Diaz et al. (25) would support this because given a repli-
cative advantage for mtDNA deletions was only found under
relaxed copy number control in the mtDNA deletion cytoplasts.
No accumulation of, or selective advantage for, mtDNA dele-
tions was reported under normal copy number control (25), in
agreement with our own findings in patient tissue. The rate of
mtDNA replication might be very important during the
process of mtDNA deletion formation and in establishing
which deletions clonally expand, but not the rate of clonal expan-
sion once the deletions have become established. In addition, the
clonal expansions we detected were associated with a clear bio-
chemical defect. Under these circumstances the pressure of
mitochondrial biogenesis may have overwhelmed any effect of
deletion size. This could explain the difference in our findings
and those of Moraes et al. in the mitoPst1 mouse, where there
was no biochemical defect. We did observe a high prevalence
of larger mtDNA deletions in the clonally expanded segments
(75% were .5 kb and 50% were .6.5 kb); this is in keeping
with the observation of an mtDNA deletion size distribution in
COX-deficient fibre regions where 70% were .5 kb and 45%
were .6.75 kb in aged muscle fibres in human skeletal muscle
(26). However, this could also be due to larger deletions being
formed more easily following an initial mutation event.
There are still many uncertainties in our understanding of
mitochondrial biology in muscle cells. We have assumed that
the size of COX-deficient segments correlates with the rate of
clonal expansion but of course other factors would influence
Figure 2. Images of ‘large’ and ‘small’ COX-deficient fibre regions selected for
extraction by laser microdissection. Panel of 10 images of longitudinal muscle
sections examined using COX/SDH histochemistry, captured prior to laser
microdissection—these are representative of typical cutting areas. (A–E)
Depict five large COX-deficient fibre regions, where the outlined region of COX-
deficiency exceeds 500 mm in length. (F–J) Depict five small COX-deficient
fibre regions, where the outlined region of COX-deficiency remains under
200 mm in length. All LMD cutting areas for single fibre isolation are outlined
in red.
Figure 3.Assessment of COX-deficient fibres captured by laser microdissection.
Scatter plot of all captured COX-deficient fibre areas (mm2), as measured by the
LMD system. Captured fibres were grouped into two types; short (under 200 mm
in length) and large (over 500 mm in length). Captured area was assessed to
ensure no overlap existed in terms of size between these two groups. Small COX-
deficient fibres: mean COX-deficient fibre area ¼ 5725+3194 mm2. Large
COX-deficient fibres: mean COX-deficient fibre area ¼ 32 120+3194 mm2.
The two groups of COX-deficient muscle fibre areas were found to be significant-
ly different using a Mann–Whitney test (P, 0.0001).
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this such as the structure of the muscle itself, rate of mitochon-
drial fission and fusion, and movement of mitochondria in and
out of the respiratory deficient region of the fibre. However, if
we assume that these would be the same for long and short
respiratory deficient segments then the lack of any evident differ-
ence in deletion size within an individual does not favour a
greater rate of clonal expansion of the larger deletions.
Another challenge when considering our results is the natural
history of the respiratory deficient segments. The variation in
segment size is well documented but it is not known whether
these segments gradually increase in size or are constantly
being lost over time. We are not aware of any longitudinal
studies that have looked at this in detail, though an accumulation
of mtDNA deletions over time has been shown to lead to fibre
loss and breakage in a rat model (27). It is therefore possible
that the size of the respiratory deficient segment is due to
factors other than the rate of clonal expansion, although the evi-
dence of increased mitochondrial biogenesis in the presence of a
respiratory chain defect (28) suggests it will have a role.
The importance of clonal expansion in causing cellular path-
ology in ageing and disease is highlighted by the ability of cells to
maintain normal function in the presence of low-level mtDNA
deletions; the initial mtDNA deletion formation event would
be unlikely to lead to a biochemical defect without the interces-
sion of clonal expansion. It is consequently of paramount import-
ance to understand the mechanism by which clonal expansion
occurs in order to prevent the consequences of mitochondrial
deficiency in ageing and disease. We have observed no variation
in the ability of mtDNA deletions of different sizes to accumulate
longitudinally through skeletal muscle fibres, leading us to the
conclusion that smaller mtDNA molecules do not possess a rep-
licative advantage to drive forward clonal expansion in human
muscle. While we have focussed upon the finding that smaller
genome size is not an advantage, it is important to note that we
have seen no trend toward a greater rate of clonal expansion
for the smallest mtDNA deletions either; this implies that no dis-
advantage is associated with losing larger sections of the genome
through a deletion event. Overall, we have found no evidence to
Table 1. mtDNA deletion sizes in COX-deficient fibre regions as determined by PCR/gel electrophoresis and mtDNA breakpoint sequencing
COX-
deficient
fibre
Estimated mtDNA
deletion length (kb)
Verified mtDNA
deletion length
(bp)
Size
difference
(bp)
5′ Deletion
breakpoint
5′ Breakpoint
sequence
3′ Deletion
breakpoint
3′ Breakpoint
sequence
Breakpoint
repeat type
1 3.5 3715 215 9576 atcaccccgc 13 291 acaatcggca No repeat
2 3.5 3904 404 10 265 tctagaaatt 14 269 atcctcccga No repeat
3 5 4977 23 8482 tccctcacca 13 459 tccctcacca Direct repeat
4 6.5 6994 444 9075 aatatcaacc 16 069 aagtattgac No repeat
5 7 7479 479 7939 actaatcttc 15 436 agacgccctc Imperfect
repeat
(4/10)
6 7.5 7648 148 6341 agacctaacc 13 989 gcccctactc Imperfect
repeat
(5/10)
7 8.5 8493 7 5438 aaaacccacc 13 931 accctagcat No repeat
8 9 9033 33 6558 aacaccacct 15 591 caattctccg Imperfect
repeat
(4/10)
9 9 9026 26 6634 ctgaagttta 15 660 caataatccc No repeat
10 9 9120 120 6468 tgatccgtcc 15 588 acacaattct No repeat
11 2.5 2880 120 7236 gactaccccg 9516 ttttaccact Imperfect
repeat
(5/10)
12 5 4977 23 8482 tccctcacca 13 459 tccctcacca Direct repeat
13 6 5647 353 7406 ccccccaccc 13 053 catagaaggc No repeat
14 6.5 6175 325 7947 tcaactccta 14 122 ttcccactca Imperfect
repeat
(4/10)
15 7.5 7046 464 5787 aagctgcttc 12 833 atgccaacac Imperfect
repeat
(4/10)
16 9.5 9044 456 6105 ataatcttct 15 149 gtcctcccgt Imperfect
repeat
(4/10)
17 10 9846 154 5341 ttaacctcta 15 187 agtaattaca No repeat
18 6.5 6927 427 8734 acctgatctc 15 661 aataatcccc No repeat
19 8 8026 26 7634 tcccctatca 15 660 caataatccc No repeat
20 3 3250 250 12 140 tcctcttgta 15 390 cctcccattc No repeat
COX-deficient fibres 1–10 were small COX-deficient fibres, while 11–20 were large COX-deficient fibres. Estimated mtDNA deletion length refers to mtDNA
deletion size as measured to the nearest 0.5 kb by long-range PCR and gel electrophoresis, while verified mtDNA deletion size refers to the deletion size ascertained by
breakpoint sequencing; size difference refers to any discrepancy between the estimated and verified mtDNA deletion sizes in base-pairs. mtDNA sequences of 10 bp
are supplied 5′ and 3′ of the mtDNA deletion, with repeated bases in bold and italicized. Two direct repeats (identical flanking sequences) and seven imperfect repeats
(4–9 bp repeated between flanking sequences) were identified.
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Figure 4.mtDNA deletion sizes present in (A) the total dataset, and (B–G) datasets from each patient. Assessment of mtDNA deletion sizes present in large and small
COX-deficient fibres, depicted by scatter plot and carried out by Mann–WhitneyU test (non-Gaussian data distribution) or unpaired t-test (normally distributed data).
(A) Small COX-deficient fibres, mean mtDNA deletion size ¼ 6589 bp (+2788 bp, N ¼ 62); large COX-deficient fibres, mean mtDNA deletion size ¼ 6508 bp
(+2478 bp,N ¼ 60). No significant difference was found to exist between the two fibre groups (P ¼ 0.5506), with a similar range of mtDNA deletion sizes displayed
in both. Similar results are seen for each of the six patient datasets (B–G), with no significant difference in deletion size between the two fibre groups in any single case
(P ¼ 0.7009, 0.7751, 0.4136, 0.8272, 2303 and 0.3406, respectively).
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support the presence of a selective pressure based upon mtDNA
deletion size to drive clonal expansion once the deletion has
formed.
MATERIALS AND METHODS
Patients and muscle biopsy samples
Skeletal muscle samples (quadriceps or biceps brachii) were
obtained by open muscle biopsy for diagnostic purposes or at
post-mortem from six patients with multiple mtDNA deletions
detected in muscle by long-range PCR and/or Southern blotting
due to a disturbance in mtDNA maintenance; five patients had a
genetic diagnosis of recessive POLG mutations, while the under-
lying molecular genetic defect in a sixth case remains undeter-
mined despite excluding commonly reported nuclear genetic
defects. A full summary of the clinical, molecular and histo-
chemical findings in all cases is presented in Table 3. The avail-
ability of large biopsy samples in these patients permitted
longitudinal sections to be cut for analysis along the length of
skeletal muscle fibres. Samples were frozen in isopentane
cooled by liquid nitrogen for histological and histocytochemical
analysis. Ethical approval for our study was obtained from New-
castle and North Tyneside LREC.
Mitochondrial enzyme histochemistry
Cryostat sections were cut at a thickness of 20 mm from longitu-
dinally orientated muscle blocks and mounted onto PEN mem-
brane slides (Leica Microsystems) prior to histochemical staining
as previously described for the sequential assay of COX/succinate
dehydrogenase (SDH) activity (32). Briefly, sections were reacted
for 45 min at 378C with COX reaction media (4 mM diaminoben-
zidine tetrahydrochloride, 100 mM, cytochrome c and 20 mg/ml
catalase in 0.2 mM phosphate buffer, pH 7.0) and 40 min at 378C
with SDH media (1.5 mM nitroblue tetrazolium, 1 mM sodium
azide, 200 mM phenazine methosulphate, 130 mM sodium succin-
ate, in 0.2M phosphate buffer, pH 7.0).
Single cell laser microdissection and cell lysis
COX-deficient areas of muscle fibres were isolated by laser
microdissection (laser microdissection (LMD) 6000; Leica
Microsystems) and collected into the cap of a 0.5 ml microcentri-
fuge cap (Eppendorf, UK). The size of the area to be cut was mea-
sured, using the Leica Microsystems software, and recorded.
Isolated COX-deficient muscle fibre regions were lysed in 15 ml
of single cell lysis buffer (500 mM Tris–HCl, 1% Tween 20,
dH20, 1% proteinase K) and incubated at 558C for 2 h followed
by 958C for 10 min.
Long-extension PCR to detect mtDNA deletions
We used long-extension PCR to detect and characterize mtDNA
deletions within individual COX-deficient muscle fibres. Over
the course of the study, two sets of primer pairs were used; one
set amplified a 13.5 kb region of the major arc (amplifying
between mtDNA nucleotides 2999–16 450; GenBank Acces-
sion number: NC_012920.1), whilst a second primer set ampli-
fied a 10.0 kb region within the same section of the major
arc of the mitochondrial genome (nucleotides 6240–16 132).
Both sets of data were used—28 fibres were investigated with
the 13.5 kb PCR, while the remaining 94 fibres were assessed
using the 10 kb assay.
For the PCR reaction, 1 ml cell lysate was added to PCR mas-
termix (dH2O, LA buffer (TaKaRa), 10 mM dNTPs, 20 mM
forward and reverse primers and LA Taq enzyme (TaKaRa), to
a total volume of 50 ml. DNA was then amplified under cycle
conditions: 948C for 1 min; 35 cycles of 948C for 30 s, 588C
for 30 s and 688C for 11 min; final extension of 728C for
10 min. PCR products were separated through a 0.7% agarose
gel with a 1 kb ladder used to size PCR amplimers.
mtDNA sequencing analysis
Long-range PCR amplimers were directly sequenced using
primers close to the predicted mtDNA deletion breakpoint
Table2. Averagedeletionsizes of ‘large’ and ‘small’ COX-deficient fibres in six
individual multiple mtDNA deletion patients.
Patient Small fibre,
average deletion
size (kb)
Large fibre,
average deletion
size (kb)
Difference of deletion size
in large fibres compared
with small fibers (kb)
1 N ¼ 14,
5.71+2.66
N ¼ 11,
6.68+1.21
+0.97, P ¼ 0.7009
2 N ¼ 7,
4.36+2.30
N ¼ 5,
3.70+3.09
20.66, P ¼ 0.7751
3 N ¼ 15,
6.30+2.43
N ¼ 12,
5.58+1.94
20.72, P ¼ 0.4136
4 N ¼ 10,
9.25+2.02
N ¼ 12,
9.34+1.61
+0.13, P ¼ 0.8727
5 N ¼ 4,
7.63+0.97
N ¼ 7,
5.71+2.34
21.91, P ¼ 0.2303
6 N ¼ 12,
6.71+2.83
N ¼ 13,
6.08+2.06
20.63, P ¼ 0.3406
Total N ¼ 62,
6.59+2.79
N ¼ 60,
6.51+2.48
20.08, P ¼ 0.5506
No trend was observed across the six patient biopsies investigated for large
mtDNA deletions to associate with either small or large regions of
COX-deficiency in muscle fibres.
Figure 5. Correlation between mtDNA deletion size and COX-deficient fibre
area.Spearman’scorrelation analysiscarriedout on the totaldata set of122 COX-
deficient skeletal muscle fibre regions, to determine if any relationship exists
between mtDNA deletion size and the size of the resulting area of biochemical
deficiency. Relationship between these variables depicted here by scatter plot
and linear regression line. No significant correlation was found to exist
between these two parameters (P ¼ 0.7792).
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(BigDye Termination Chemistry on ABI 3130xl genetic analys-
er; Applied Biosystems); the predicted breakpoint location was
determined using a restriction digest with four restriction endo-
nucleases (XhoI,BamHI,XcmI andDraI, New England Biolabs)
(33). ABI PRISM SeqScape Software Version 2.6 was used to
identify mtDNA deletion breakpoints, and accurately determine
the size of the deleted region of mtDNA.
Statistical analysis
All statistical analysis was carried out using GraphPad Prism v.4
statistical software. Group comparisons were made using un-
paired t-tests or Mann–Whitney tests, and data correlation was
assessed using a two-tailed Spearman or Pearson correlation
test at 95% confidence; relevant tests were chosen based upon
data distribution (i.e. depending upon whether or not the
spread of data followed a normal distribution, in order to maxi-
mize the power of each statistical analysis). An a priori power
analysis was carried out in order to calculate the minimum
sample size required to observe a significant difference in dele-
tion size between ‘large’ and ‘small’ COX-deficient regions.
This test was carried out using the highest standard deviation
seen within the groups (2.74 kb), demonstrating a need for a
minimum of 36 samples per group to observe a difference in
mtDNA deletion size of at least 2 kb.
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